Emmaus Life Sciences, Inc. (EMMA)

Overview

Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company focused on the discovery, development, marketing, and sales of innovative treatments and therapies for rare and orphan diseases. With a global operational footprint, the company aims to address unmet medical needs primarily in the United States and internationally. Originally established as Emmaus Holdings, Inc., it underwent a name change to Emmaus Life Sciences, Inc. in September 2011. Since its inception in 2000, the company has been headquartered in Torrance, California, demonstrating a sustained commitment to combating some of the most challenging diseases with significant unaddressed medical needs.

Products and Services

• Endari

Emmaus Life Sciences, Inc.'s flagship product, Endari, is an innovative treatment revolutionizing the management of sickle cell disease. Endari, an L-glutamine oral powder, has been meticulously designed to reduce the acute complications associated with sickle cell disease in both adult and pediatric patients aged five years and older. This product stands as a testament to Emmaus Life Sciences, Inc.'s dedication to enhancing the quality of life for patients suffering from this debilitating condition.

• Collaboration with Kainos Medicine, Inc.

In its endeavor to expand its portfolio and impact within the biopharmaceutical industry, Emmaus Life Sciences, Inc. has entered into a collaboration agreement with Kainos Medicine, Inc. This strategic partnership is focused on the preclinical development of KM10544, a patented IRAK4 inhibitor, as an anti-cancer drug. The collaboration highlights Emmaus Life Sciences, Inc.'s commitment to exploring new therapeutic areas and harnessing innovative technologies to combat cancer.